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ABSTRACT
Endothelial-like progenitor cells circulate in the peripheral blood (PB) and can be enumerated using cell
culture-based progenitor assays. These circulating vascular progenitor cells (VPCs) are implicated in new
vessel formation and regenerative potential in several animal and human models of tissue injury. Given the
emerging role of VPCs in regenerative processes and the limited information on the availability of such
progenitor cells, we sought to determine baseline circulating VPC levels in healthy allogeneic donors and
autologous hematopoietic transplant patients. VPC numbers were also measured in peripheral blood stem cell
(PBSC) grafts from both graft types. Immunohistochemistry revealed that VPC clusters obtained under our
culture conditions were CD45 and acquired endothelial features (CD31 and vascular endothelial-cadherin) in
vitro upon angiogenic stimulation and gradually lost monocytic surface markers (CD14). Before PBSC
mobilization, VPCs levels varied substantially in healthy donors and were markedly lower in patients with
hematologic malignancies compared with healthy allogeneic donors with 27  15 versus 99  21 VPCs/mL
(mean  SEM), respectively (P  .001). In patients undergoing stem cell mobilization, VPCs in the PB
increased from 7  2 on day 0 to 51  9 by day 7 of mobilization (P  .05), representing a median fold increase
of 8.9 (range, 3.0-29.8). Although autologous transplant patients underwent more intensive mobilization,
VPCs were higher in allogeneic (7.2  1.4  103/kg) than in autologous (2.6  1.5  103/kg) mobilized PB
grafts (P .045). To identify predictors of VPC content, graft VPCs were compared with levels of CD34 cells,
total colony forming unit (CFU), or granulocyte-macrophage colony forming unit (GM-CFU). None of these
hematopoietic progenitors correlated with VPC numbers in PBSC grafts (P  NS). However, PB monocyte
levels were highly correlated with circulating VPC levels (r  0.71, P < .0001). Thus, our analysis identified
significant variability in VPCs at baseline and in PBSC grafts from healthy donors. Nevertheless, these donors
remain a better source of VPCs than do autologous transplant patients. Importantly, VPC mobilization occurs
independently of hematopoietic mobilization. In view of the potential role of VPCs in recovery from trans-
plant-related tissue injury, angiogenic mobilization strategies that complement hematopoietic mobilization
will need to be specifically designed.
© 2007 American Society for Blood and Marrow Transplantation
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cNTRODUCTION
Circulating endothelial-like or vascular precursor
ells (VPCs) have the potential to form new blood
essels and assist in the repair of ischemic tissues [1]. fhe development of in vitro culture assays in combi-
ation with delineation of endothelial surface antigens
as enabled the identiﬁcation of early outgrowth cell
lusters as VPCs [2,3]. Using such assays, VPCs were
ound to increase in human peripheral blood (PB) in
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D. S. Allan et al.434esponse to ischemic injury such as burns and myo-
ardial infarcts [4,5]. Interestingly, VPC levels corre-
ate well with serum levels of growth factors released
uring ischemic injury and with known vascular ef-
ects such as vascular endothelial growth factor and
rythropoietin. In addition, higher levels of VPCs in
uman PB reﬂect superior vascular function and a
ore favorable cardiovascular risk proﬁle [2]. More-
ver, recent evidence from animal models suggests
hat cells with endothelial properties may promote
rgan regeneration and functional repair after stroke
6,7], acute coronary ischemia [8], and drug-induced
ancreatic injury [9]. Evidence from animal models
lso suggests that VPCs may be mobilized in re-
ponse to cytokine growth factors oriented toward
he myeloid and erythroid lineages such as G-CSF
10], granulocyte-macrophage colony stimulating fac-
or (GM-CSF) [11], and erythropoietin [12,13]. Cy-
okine growth factor usage to promote the transloca-
ion into the PB of hematopoietic progenitors, or
PCs in particular, may enhance tissue healing after
yocardial damage and other organ injury [14,15].
owever, limited information is available on VPC
evels present in humans at steady state and after
obilization in healthy donors and cancer patients. In
ddition, the ability of hematopoietic progenitor cells
o reﬂect VPC content has not been ascertained. An
mproved understanding of how mobilization agents
nﬂuence VPCs is needed to more clearly deﬁne the
otential role of hematopoietic grafts in decreasing
ascular toxicity induced by high-dose chemotherapy
nd radiation [16,17] and in other clinical regenerative
herapies [6-9,15].
In the present study, we found that healthy donors
xposed to identical hematopoietic growth factor
oses demonstrate major differences in VPC levels.
e also provide evidence that patients with hemato-
ogic cancers harbor lower circulating and postmobi-
ization VPC levels. Importantly, the present data
upport independent mobilization of cells with regen-
rative potential and hematopoietic reconstitution
bility.
ETHODS
atients and Samples
Blood samples were obtained with the written
nformed consent of patients and healthy volunteers at
he Hopital Maisonneuve-Rosemont and studies per-
ormed on site under protocols approved by the hos-
ital human ethics and scientiﬁc review committees.
ll patients who underwent mobilization of autolo-
ous PB stem cells received the same mobilization
egimen consisting of cyclophosphamide 1.5 g/m2 i.v.
n day 0 followed by recombinant human G-CSF
Neupogen, Amgen Inc, Thousand Oaks, Calif, USA) Ct 10 g/(kg · d) subcutaneously for 10 d (Table 1).
onors for allogeneic transplantation were mobilized
ith G-CSF at 10 g/(kg · d) subcutaneously for 5 d.
pheresis was performed when CD34 cells exceeded
0/L in the PB. CD34 cell determinations were
erformed in accordance with International Society of
ematotherapy and Graft Engineering guidelines
18,19]. PB samples were drawn into sterile tubes
ontaining EDTA and mononuclear cells (MNCs)
eparated by Ficoll-Hypaque density centrifugation.
PC Cluster Assay
Peripheral blood MNCs were cultured at 5.0 
06 cells/well in ﬁbronectin-coated 6-well culture
ishes (Biocoat, BD Biosciences, Bedford, Mass, USA)
n RPMI-1640 medium (Sigma Aldrich, Germany)
upplemented with 20% FCS (HyClone, Logan,
tah, USA), 50 g/mL endothelial cell growth factor
Roche Diagnostics, Mannheim, Germany), and 10
U/mL heparin (Leo Pharmaceuticals, Thornhill,
anada) according to previously described methodol-
gies [2,3]. Nonadherent cells were collected after
8 h, washed, and replated at 1.0  106 cells/well
n 24-well ﬁbronectin-coated dishes. Medium and
rowth factors were replaced every 2 d. VPC clusters
ere enumerated 7 d after replating under an inverted
hase microscope. VPC clusters were deﬁned as clus-
ers of 30 cells with 3 attached projecting cells
2,3].
mmunohistochemistry of Cell Clusters
n VPC Assay
To conﬁrm the vascular nature of the clusters,
ndividual cell clusters were plucked from culture
ishes at day 7 or 14 and cytospun onto glass slides.
ells were incubated with primary mouse monoclonal
nti-human antibodies against CD45 (Immunotech,
arseille, France), CD14 (Immunotech), CD31 (Dako
able 1. Characteristics of Patients Undergoing Autologous
obilization
o. of patients 10
ge (yr), median (range) 55 (35-67)
o. of men (%) 8 (80)
iagnosis, n (%)
Multiple myeloma 6 (60)
NHL 3 (30)
HD 1 (10)
o. of previous chemotherapy regimes,
median (range) 1 (1-4)
o. of cycles of previous chemotherapy,
median (range) 5 (4-14)
o. patients undergoing collection (%) 8 (80)
o. collections, median (range) 2 (1-3)
D34/kg total, median (range) 7.2  106 (2.0-13.1)
D indicates Hodgkin’s disease; NHL, non-Hodgkin’s lymphoma.ytomation, Glostrup, Denmark), and vascular endo-
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Vascular Progenitors in Stem Cell Grafts 435helial-cadherin (BD PharMingen, San Diego, Calif,
SA) at 5 g/mL. Mouse IgG1 (BD PharMingen)
nd IgG2A (Dako) were used as negative control re-
gents. Immunohistochemical analysis was performed
sing an avidin-biotin labeling technique (LSAB 2
ystem, Dako Corp, Carpinteria, Calif, USA) accord-
ng to the manufacturer’s instructions. Human umbil-
cal vein endothelial cells were used as positive con-
rols for endothelial antigens (gift from Dr Lisheng
ang, University of Ottawa, Canada).
ematopoietic Progenitors
Hematopoietic clonogenic progenitors in patient
nd healthy donor samples were measured after seed-
ng in Methocult H4434 (Stem Cell Technologies,
ancouver, Canada) as previously described [20]. Col-
ny forming units (CFUs) were assessed by morphol-
gy and enumerated after incubation for 14 d at 37°C
n 5% CO2 humidiﬁed atmosphere. CD34
 cell con-
ent in apheresis products was determined using a
ual-platform ﬂow cytometric technique in accor-
ance with International Society of Hematotherapy
nd Graft Engineering recommendations [18].
tatistical Analysis
Student t test was used for comparative statistical
esting using 2-tailed analysis and unequal variance.
EM is reported for all mean values. Nonparametric
nconstrained correlation analysis was performed and
he Spearman coefﬁcient (r) is reported. Wilcoxon
ank-sum test was used to compare linear regression
ith the null hypothesis with a 95% conﬁdence inter-
al. To ensure that differences observed were not
elated to age, VPC levels in cancer patients were
ompared with those of a subgroup of healthy volun-
eers demonstrating similar age characteristics using
able 2. Immunohistochemistry of VPCs*
CD45 CD14 CD31 VE-Cadherin
ontrols
HUVEC    
AML-M5    
ngiogenic conditions
VPC  /  /
erum only
VPC  /  /
UVEC indicates human umbilical vein endothelial cell; , no
positive cells; , 10% of cells positive; , 10%-80% of cells
positive; , 80% of cells positive.
Individual VPC colonies were plucked and stained by immunohis-
tochemistry (all cytospins) using an alkaline phosphatase detec-
tion method. Angiogenic conditions incorporated 20% FCS
supplemented with endothelial cell growth factor (50 g/mL)
and heparin (10 IU/mL); see Methods.tudent t test. vESULTS
PCs Acquire Endothelial Features after In Vitro
xposure to Angiogenic Conditions
To ensure in vitro recognition of VPCs, individual
lusters grown under angiogenic culture conditions
ere isolated and analyzed by immunohistochemistry
or expression of hematopoietic (CD45), monocytic
CD14 and CD31), and endothelial surface (CD31
nd VE-cadherin; Table 2) markers. When exposed to
ndothelial cell growth factor and heparin, cell clus-
ers demonstrated decreased CD14 and increased
D31 expression in comparison with serum-only cul-
ure conditions, whereas VE-cadherin surface expres-
ion was identical in both groups. Clusters retained
niform strong expression of the hematopoietic
arker CD45 under both culture conditions, but
hose grown without angiogenic factors had increased
xpression of monocytic antigens (CD14). Thus,
PCs were characterized as CD45 cell clusters with
ndothelial-like surface markers (CD31 and VE-cad-
erin) and residual CD14 expression.
PC Levels in Healthy Donors and Patients with
ematologic Malignancies
Patients undergoing autologous transplantation
ere exposed to chemotherapeutic agents in an at-
empt to achieve disease control. Because these agents
ould affect the hematopoietic cell pool, they could
lso impair VPC production. To determine whether
atients with hematologic malignancies had decreased
evels of vascular progenitors, VPCs were enumerated
n the PB of healthy volunteers (n  21) and patients
ith hematologic malignancies (n  10, 6 with multiple
yeloma and 4 with lymphoma; Figure 1). Patients had
eceived a median of 1 previous chemotherapy regimen
range, 1-4) and 5 treatment cycles (range, 4-14). All
igure 1. VPCs in healthy donors and patients with hematologic
alignancies. (A) VPCs enumerated per milliliter of PB and (B)
PCs per 106 MNCs. Solid circles represent individual healthy
onors (n  21), open circles represent individual patients (n  10)
ith hematologic malignancies, and horizontal lines represent mean
alues.
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D. S. Allan et al.436atients were assessed at time of baseline evaluation
efore autologous stem cell transplantation. Individ-
al VPC levels demonstrated important variations
50-fold) in relation to blood volume and MNC
ontent, particularly in healthy donors. VPCs circu-
ating in the PB were signiﬁcantly decreased in pa-
ients (27 	 15/mL, mean 	 SEM) compared with
hose in healthy subjects (99	 21/mL, P .001). The
lating efﬁciency of VPCs was also decreased in pa-
ients (22 	 10 per 106 MNCs) compared with that in
ealthy volunteers (66 	 16, P  .004; Figure 1B).
ecause VPC levels have been reported to decrease
ith age, patients with malignancy (mean age, 53 yr;
ange, 35-67) were compared with healthy donors
f similar age (mean, 50 yr; range, 45-60; P  NS).
PCs remained signiﬁcantly lower in cancer patients
P  .04).
VPC deﬁciency could not be ascribed to global
eukopenia because PB leukocyte counts did not differ
etween patients and healthy volunteers (P  NS,
ata not shown). However, monocyte counts were
igniﬁcantly lower in patients (0.10 	 0.02  109/L)
ompared with those in healthy controls (0.48	 0.04
09/L, P  .0001).
PCs Increase after HSC Mobilization
In view of the VPC potential for tissue repair, we
etermined the ability of hematopoietic stem cell
HSC) mobilization to also mobilize VPCs. After cy-
lophosphamide and G-CSF mobilization, the num-
er of circulating VPCs increased from 7 	 2/mL PB
mean 	 SEM) on day 0 to 51 	 9 by day 7 of
obilization (P  .05; Figure 2). In addition, all pa-
ients studied had an increase in PB VPC numbers
esulting in a median 8.9-fold expansion of the VPC
ompartment (range, 3.0-29.8).
igure 2. Mobilization of VPCs in candidates for autologous
BSCT. Circles represent individual patient values from PB im-
ediately before and after stem cell mobilization, and horizontalPines represents mean values.egenerative Content of Allogeneic and
utologous Stem Cell Grafts
To determine if patients administered allogeneic
SC grafts receive larger amounts of VPCs than their
utologous transplant counterparts, VPCs were quan-
iﬁed in the apheresis products of normal allogeneic
SCT donors and autologous transplant patients
Figure 3). Mean ages of allogeneic donors and pa-
ients undergoing autologous transplantation were
dentical (51 	 2 versus 51 	 5 yr, respectively, P 
S). Larger numbers of graft VPCs were found in
llogeneic collections (7.2 	 1.4  103/kg) compared
ith autologously mobilized collections (2.6 	 1.5 
03/kg, P  .045). When considered according to
raft cellularity, VPCs remained more numerous in
llogeneic than in autologous grafts (8.3 	 1.6 versus
.8 	 1.2 per 106 MNCs, P  .015). However,
D34 cells, total CFUs, and GM-CFUs per kilo-
ram were not statistically different between alloge-
eic and autologous grafts (P  .86, .83, and .85,
espectively, for these comparisons, data not shown).
redictors of VPC Content
To determine whether VPC numbers could be
redicted from hematopoietic progenitor cell content,
raft VPCs were evaluated in comparison with
D34 cell numbers, total CFU, and GM-CFU lev-
ls. Although total CFUs, GM-CFUs, and CD34
ell counts demonstrated an excellent correlation with
ach other (no independent variable identiﬁed on mul-
iple linear regression analysis, P  NS), none of these
ematopoietic parameters correlated with VPCs ad-
inistered or VPC cellularity in PBSC grafts (Table 3;
igure 3. VPCs in PBSC grafts from healthy donors and patients
ith hematologic malignancies. (A) VPCs  103/kg recipient
eight, and (B) VPCs per 106 MNC. Solid circles represent indi-
idual values from healthy allogeneic donor grafts, open circles
epresent individual values from autologous collections in patients
ith hematologic malignancies, and horizontal bars represents
ean values. NS). The absence of correlation was also sus-
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Vascular Progenitors in Stem Cell Grafts 437ained when autologous and allogeneic grafts were
valuated independently (data not shown). Because
PC numbers failed to correlate with usual hemato-
oietic progenitor cells, we investigated whether they
ould correlate with cells potentially involved in the
eneration of VPCs, such as monocytes. Interestingly,
B monocyte levels were highly correlated with cir-
ulating VPC levels (r 0.71, P .0001; Figure 4). In
ddition, VPC levels in PB were not signiﬁcantly
ifferent between patients and healthy volunteers
hen normalized for the decreased CD14 cell con-
ent (1.68 versus 1.54 VPCs per 104 CD14 cells,
 .89).
ISCUSSION
Regardless of their precise origin, VPCs can be
numerated and characterized using in vitro culture
ssays, immunohistochemical analysis, or ﬂow cytom-
try. Consistent with our own data, other groups have
emonstrated that VPCs form cell clusters and attach-
able 3. Lack of Correlation Between VPCs and Hematopoietic
rogenitors in PBSC Grafts
Comparison n r (95% CI) P
D34 cells  106/kg vs
VPCs/kg 19 0.030 (0.49 to 0.44) 0.9
otal CFUs/5  104 MNCs vs
VPCs/106 MNCs 14 0.042 (0.57 to 0.51) 0.9
otal CFUs/kg vs VPCs/kg 14 0.48 (0.08 to 0.81) 0.08
M-CFUs/5  104 MNCs vs
VPCs/106 MNCs 14 0.013 (0.55 to 0.53) 0.96
M-CFUs/kg vs VPCs/kg 14 0.25 (0.34 to 0.70) 0.38
I indicates conﬁdence interval.
igure 4. Relation between VPCs and monocytes in PB presented
n  18) and autologous transplant patients before mobilization o
oefﬁcient.ng cells under angiogenic stimulation and variably
xpress Von Willebrand factor, VE-cadherin, vascular
ndothelial growth factor receptor 2 (kinase insert
omain containing receptor) and take up acetylated
ow density lipoprotein [1,5,21]. Hill et al [2] also
eported that similar cell clusters can be derived from
he PB of patients after ex vivo culture in serum-rich
onditions, without speciﬁc angiogenic stimulation.
owever, our immunohistochemical analysis of VPC
lusters showed that PB vascular progenitors identiﬁed
y early outgrowth from ex vivo culture acquired more
eﬁned endothelial surface markers under angiogenic
onditions than under serum-only conditions. In addi-
ion, cell clusters evaluated in these conditions corre-
ate well with classic risk factors of cardiovascular
ealth [2]. Based on these observations and the fact
hat the infusion of such endothelial-like attaching
ells and cell clusters has mediated tissue repair in
everal animal models of ischemic injury [7,21,22] and
n humans with myocardial infarction [8], we per-
ormed VPC assessment using a clonogenic approach
nd angiogenic stimulation.
In our study, VPCs were signiﬁcantly depleted in
he PB of patients with hematologic malignancy com-
ared with healthy volunteers. The fact that all pa-
ients had received chemotherapy before mobilization
ay have contributed to lower VPC levels. One pre-
ious report described a decrease in VPC numbers
ith age in patients with cardiovascular disease [23].
owever, in the present study, when cancer patient
esults were compared with those of age-matched
ealthy donors, VPC numbers remained lower in can-
er patients, conﬁrming the age-independent nature
f this effect. The effect of hematologic malignancy
s per milliliter of PB and monocytes in PB in healthy volunteers
s (n  7). Regression analysis (r) was according to the Spearmanas VPC
f PBSC
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D. S. Allan et al.438tself and the possible role of chemotherapy on VPC
eserves have obvious implications for harnessing the
herapeutic potential of these cells. Although not de-
ectable in the present study, VPC content could also
ary according to type of malignancy. Lower levels of
onocytes in the PB of cancer patients may explain
he decrease in VPCs. However, VPC levels in grafts
id not correlate with GM-CFU levels and further
ork is needed to clarify the association between
onocytic lineage and VPCs. The identiﬁcation of
mportant differences in baseline levels of VPCs may
ranslate into variable tissue repair capabilities be-
ween individuals, with cancer patients demonstrating
particularly limited potential to recover from vascu-
ar damage.
Using standard mobilization strategies, we have
hown that VPCs were increased during autologous
B HSC mobilization. Despite a nearly 10-fold in-
rease in VPC numbers during autologous mobiliza-
ion, VPC levels in cancer patients did not reach
aseline levels of normal healthy volunteers. In addi-
ion, the VPC content in PBSC grafts of autologous
atients was lower than in allogeneic grafts, notwith-
tanding the use of a more aggressive HSC mobiliza-
ion scheme that included chemotherapy in addition
o G-CSF. Importantly, we have not addressed the
ffect of cyclophosphamide given to patients as part of
he mobilization scheme. Future studies are needed to
etermine the effect of cyclophosphamide and other
hemotherapeutic agents on the mobilization of VPCs.
Our analysis of PBSC grafts showed further that
PC mobilization occurred independently of hema-
opoietic progenitor cell mobilization. No relation
etween graft CD34 content and VPC numbers
ould be found. Even granulocyte-monocyte progen-
tors (CFU-GM), which could relate to VPC precur-
ors, and the more global total CFU content could not
e linked to VPC yields. Evidence supports the exis-
ence of rare adult hemangioblast cells in quiescent
one marrow niches that can recapitulate all hemato-
oietic lineages and also exhibit endothelial precursor
roperties including neovascularization potential [24-
7]. However, hemangioblast progeny, that includes
PCs and hematopoietic progenitors, may contribute
nly a small pool of circulating vascular progenitors.
ascular regeneration and angiogenesis could also
ely on more committed endothelial precursors aris-
ng from adult vessels [3]. Unfortunately, the inabil-
ty of surrogate markers for stem cells to predict for
PC content represents an important limitation.
PCs will have to be measured independently by
sing clonogenic assays that require several days.
he study of potential precursor cell populations
nd antigenic structures on rare populations related
o vascular cell regeneration will be most important
o accurately identify VPCs within a short period,ommensurate with the development of selective
ollection strategies.
Cells of the monocyte lineage may repair damaged
essels after migrating into surrounding tissues [28-
0]. Several groups have demonstrated the induction
f an endothelial phenotype from CD14 monocytes
nder angiogenic culture conditions [28-32]. Interest-
ngly, our study identiﬁed a relation between PB
onocytes and levels of circulating VPCs. This ﬁnd-
ng is consistent with the notion that VPC clusters
rown in cell culture retain some monocytic surface
arkers. It is also in line with the ﬁnding of lower
eripheral monocyte levels in hematologic cancer pa-
ients than in healthy controls. In view of these ﬁnd-
ngs and the known role of monocytes in tissue repair,
e intend to further evaluate monocyte populations as
predictor of regenerative reserves in healthy donors
nd patients with cancer who are undergoing chemo-
herapy.
A better delineation of VPC content is of critical
mportance to optimize graft composition for regen-
rative applications. Moreover, devising angiogenic
obilization strategies that complement hematopoi-
tic mobilization might lead to direly needed strate-
ies to reduce transplant-related toxicity after alloge-
eic and autologous transplantations.
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